Hydroxychloroquine-Induced Myopathy Responding to Intravenous Immunoglobulin (IVIG)

نویسندگان

چکیده

Hydroxychloroquine (HCQ), a drug used to treat many diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), has limited reports documenting drug-induced myopathies side effect. This entity is underdiagnosed with unclear treatment interventions apart from discontinuing the offending drug. We report case of biopsy-proven hydroxychloroquine-induced myopathy in 35-year-old female patient SLE. The was stopped, but did not improve. However, she showed marked improvement after use intravenous immunoglobulin (IVIG).

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Intravenous immunoglobulin (IVIG) therapy for immunologic abortion

Recurrent pregnancy loss associated with immunologic abnormalities has been termed immunologic abortion. Immunologic abortion occurs primarily in women over the age of 30 years and may affect either natural or in-vitro fertilization (IVF)-induced pregnancy. In this article, we review the humoral and cellular immunologic abnormalities that have been associated with this form of recurrent abortio...

متن کامل

Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss.

I b a t fi ACKGROUND ome cases of unexplained recurrent spontaneous pregnancy oss have been proposed to arise from an undefined immuological barrier to normal placentation. One proposed treatent, active immunization with allogeneic leukocytes, benfits only 8% to 10% of treated couples, who cannot be elected by means of diagnostic testing (1). Another treatent, passive immunization with intraven...

متن کامل

Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation.

were involved in the care of the patients and contributed clinical samples and data. inhibition with ruxolitinib versus best available therapy for myelofibrosis.term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. We recently reported that intravenous immunoglobulin (IVIg) interferes with the...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cureus

سال: 2023

ISSN: ['2168-8184']

DOI: https://doi.org/10.7759/cureus.41016